#ES­MO22: Mi­rati vs. Am­gen: Scrap­py KRAS G12C con­tender out­per­forms its gi­ant ri­val in col­orec­tal can­cer

PARIS — This week­end at ES­MO, the KRAS bat­tle be­tween Am­gen and its pesky biotech ri­vals at Mi­rati will con­tin­ue with new slices of com­bo da­ta for ad­vanced cas­es of col­orec­tal can­cer. And once again, Mi­rati will get in with a sol­id punch.

Am­gen has up­dat­ed com­bi­na­tion da­ta on its ap­proved pi­o­neer Lumakras and its EGFR in­hibitor Vectibix with a 30% over­all re­sponse rate — way bet­ter than the mea­ger 9.3% it post­ed ear­li­er for the monother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER